Vaccine. 2007 Jan 2;25(1):55-63. Epub 2006 Jul 31.

Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.

Baker CJ, Rench MA, Paoletti LC, Edwards MS.

Source

Section of Infectious Diseases, Department of Pediatrics, Room 302A, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States. cbaker@bcm.tmc.edu

Abstract

A phase 1, dose-escalating trial was conducted in healthy adults to evaluate immunogenicity and reactogenicity of a type V group B streptococcal (GBS) capsular polysaccharide (CPS)-tetanus toxoid (TT) conjugate vaccine. Participants received one dose of unconjugated V CPS (37 microg), V-TT (2.4 microg CPS/1.1 microg TT), V-TT (9.6 microg CPS/4.3 microg TT) or V-TT (38.5 microg CPS/17.0 microg TT). Each vaccine and all doses of V-TT were well-tolerated. V CPS-specific antibodies reached a peak 4-8 weeks after immunization and were significantly higher through 52 weeks post-immunization in recipients of V-TT at each dose than in uncoupled CPS vaccinees. V-TT vaccine-induced antibodies promoted opsonophagocytic killing of type V GBS and avidity maturation of V CPS-specific IgG.

PMID:: 16919857; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Save items

Related citations in PubMed

Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. [J Infect Dis. 2004]
Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL, Rench MA, Edwards MS, Baker CJ. J Infect Dis. 2004 Aug 1; 190(3):558-64. Epub 2004 Jun 30.
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. [J Clin Invest. 1996]
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. J Clin Invest. 1996 Nov 15; 98(10):2308-14.
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. [Infect Immun. 2001]
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ. Infect Immun. 2001 Nov; 69(11):6696-701.
Review Group B streptococcal conjugate vaccines. [Arch Dis Child. 2003]
Review Group B streptococcal conjugate vaccines.
Baker CJ, Edwards MS. Arch Dis Child. 2003 May; 88(5):375-8.
Review Glycoconjugate vaccines to prevent group B streptococcal infections. [Expert Opin Biol Ther. 2003]
Review Glycoconjugate vaccines to prevent group B streptococcal infections.
Paoletti LC, Kasper DL. Expert Opin Biol Ther. 2003 Sep; 3(6):975-84.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections. [Am J Med Sci. 2010]
Review Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.
Bronze MS, Dale JB. Am J Med Sci. 2010 Sep; 340(3):218-25.
Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. [Infect Immun. 2010]
Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.
Gening ML, Maira-Litrán T, Kropec A, Skurnik D, Grout M, Tsvetkov YE, Nifantiev NE, Pier GB. Infect Immun. 2010 Feb; 78(2):764-72. Epub 2009 Nov 30.
Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. [Proc Natl Acad Sci U S A. 2008]
Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.
Guttormsen HK, Paoletti LC, Mansfield KG, Jachymek W, Jennings HJ, Kasper DL. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5903-8. Epub 2008 Mar 31.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conj...
Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Vaccine. 2007 Jan 2 ;25(1):55-63. Epub 2006 Jul 31 .

PubMed
Relationship between intestinal permeability to [51Cr]EDTA and inflammatory acti...
Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease.
Dig Dis Sci. 1990 May ;35(5):582-8.

PubMed
Peripheral benzodiazepine receptors on platelets of fibromyalgic patients.
Peripheral benzodiazepine receptors on platelets of fibromyalgic patients.
Clin Biochem. 2006 Sep ;39(9):867-72. Epub 2006 Jul 13 .

PubMed
Neurocircuitry models of posttraumatic stress disorder and extinction: human neu...
Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research--past, present, and future.
Biol Psychiatry. 2006 Aug 15 ;60(4):376-82.

PubMed
Combination therapy with statins and omega-3 fatty acids.
Combination therapy with statins and omega-3 fatty acids.
Am J Cardiol. 2006 Aug 21 ;98(4A):34i-38i. Epub 2006 May 30 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: